BioXcel Therapeutics, Inc. (BTAI) - Dilution Analysis

10-Q filing | 30.9M shares outstanding

8-K filing: BioXcel Therapeutics, Inc. granted lenders warrants to purchase up to 1,353,729 shares of common stock at an exercise price of $0.01 per share on April 15, 2026.

10-K filing | 27.1M shares outstanding

10-Q filing | 5.5M shares outstanding

10-K filing | 3.1M shares outstanding

8-K filing: BioXcel Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of common stock and warrants.

8-K filing: Stock split 1-for-16 | Outstanding: 42,390,000 → 2,649,375

S-3 filing: This S-3 filing relates to the resale by selling stockholders of up to 5,100,000 shares of BioXcel Therapeutics, Inc.'s common stock issuable upon exercise of warrants.

8-K filing: BioXcel Therapeutics, Inc. entered into an underwriting agreement for a public offering of 5,600,000 shares of common stock and accompanying warrants, and pre-funded warrants to purchase 9,000,000 shares of common stock and accompanying warrants, at combined public offering prices of $0.48 and $0.479 respectively, resulting in net proceeds of approximately $6.2 million. ($7.0M proceeds)

8-K filing: BioXcel Therapeutics, Inc. entered into the Fifth Amendment to Credit Agreement, waiving certain covenants and agreeing to new capital raising covenants, while also issuing new warrants to lenders to purchase 5.0 million shares of common stock at $0.01 per share.

10-Q filing | 42.4M shares outstanding

10-Q filing | 40.3M shares outstanding

10-Q filing | 30.9M shares outstanding

8-K filing: BioXcel Therapeutics, Inc. entered into a Securities Purchase Agreement to issue and sell 3,054,609 shares of common stock and accompanying warrants, as well as pre-funded warrants to purchase up to 5,565,027 shares of common stock and accompanying warrants, in a registered direct offering, with expected net proceeds of approximately $24.9 million.

10-K filing | 29.1M shares outstanding

S-3 filing: BioXcel Therapeutics, Inc. is offering 69,630 shares of common stock issuable upon exercise of warrants granted in connection with that certain second amendment to credit agreement.

8-K filing: BioXcel Therapeutics amended its credit agreement, terminated its Revenue Interest Financing Agreement, amended and restated warrants to purchase up to 278,520 shares, and granted new warrants to purchase up to 69,630 shares of common stock to Lenders.

10-Q filing | 29.3M shares outstanding

S-3 filing: BioXcel Therapeutics, Inc. is offering common stock with an aggregate offering price of up to $150,000,000 and is intended to use the net proceeds of this offering to fund ongoing clinical trials, commercialization preparation and for general corporate purposes.

10-Q filing | 29.2M shares outstanding

10-Q filing | 28.6M shares outstanding

10-K filing | 28.0M shares outstanding

10-Q filing | 28.0M shares outstanding

10-Q filing | 28.0M shares outstanding

S-3 filing: BioXcel Therapeutics, Inc. is registering 278,520 shares of common stock issuable upon exercise of warrants for resale by selling stockholders.

10-Q filing | 28.0M shares outstanding

8-K filing: BioXcel Therapeutics, Inc. issued warrants to lenders to purchase up to 278,520 shares of common stock at an exercise price of $20.04 per share and granted the lenders the right to purchase shares of common stock for $5.0 million at a price per share equal to a 10% premium to the volume weighted average price of the common stock over the 30 trading days prior to the lenders' election.

10-K filing | 26.4M shares outstanding

POS AM filing: BioXcel Therapeutics is offering common stock, preferred stock, debt securities, warrants and units for a total aggregate amount of $300,000,000, and the selling securityholder may offer and sell up to an aggregate of 8,546,750 shares of common stock.

10-Q filing | 24.4M shares outstanding

10-Q filing | 24.4M shares outstanding

8-K filing: BioXcel Therapeutics, Inc. entered into an underwriting agreement for the issuance and sale of 3,155,000 shares of common stock at $31.70 per share, resulting in net proceeds of approximately $96.8 million. ($96.8M proceeds)

10-Q filing | 24.6M shares outstanding

10-K filing | 24.6M shares outstanding

10-Q filing | 24.4M shares outstanding

10-Q filing | 22.4M shares outstanding

10-Q filing | 20.2M shares outstanding

10-K filing | 20.2M shares outstanding